Laurberg Peter, Andersen Stig, Bülow Pedersen Inge, Carlé Allan
Department of Endocrinology and Medicine, Aalborg Hospital, Aarhus University Hospital, DK-9000 Aalborg, Denmark.
Drugs Aging. 2005;22(1):23-38. doi: 10.2165/00002512-200522010-00002.
Some degree of hypothyroidism is common in the elderly. It affects 5-20% of women and 3-8% of men. The occurrence varies with genetics with a high prevalence in Caucasians, and the disease is more common in populations with a high iodine intake. The common causes of hypothyroidism are autoimmune destruction of the thyroid gland and previous thyroid surgery or radioiodine therapy. Various types of medication, including amiodarone, cytokines and lithium, often induce hypothyroidism. Symptoms may be atypical and measurement of serum thyroid-stimulating hormone (TSH) levels should be part of biochemical testing for undiagnosed medical conditions in elderly subjects. The finding of an elevated serum TSH level should be confirmed by repeated testing and supplemented with measurements of serum levels of thyroxine (T(4)) and thyroid peroxidase antibodies to verify, quantify and subclassify the abnormality. The recommended and appropriate replacement therapy for hypothyroidism is levothyroxine sodium. The initial replacement dose should be low if heart disease is suspected. Because of the long half-life of levothyroxine sodium small dosage adjustments may be performed by adding or withdrawing a tablet once or twice weekly. Levothyroxine sodium is only partly absorbed after oral ingestion, and food, minerals, drugs and tablet composition influence absorption. Studies performed a few years ago suggested that a combination of levothyroxine sodium and liothyronine may improve clinical results, but recent more comprehensive studies have not supported this hypothesis. Accordingly, liothyronine replacement is not documented to be of benefit. If liothyronine is added to replacement, the liothyronine dose should be kept low, within the physiological range and, preferably be administered twice daily. Thyroid hormone therapy has no beneficial effect above placebo in elderly individuals with normal serum TSH levels and T(4) levels. The major risk of levothyroxine sodium therapy is over-replacement, with anxiety, muscle wasting, osteoporosis and atrial fibrillation as adverse effects. Subclinical hypothyroidism with elevated serum TSH levels but T(4) levels within the laboratory reference range is a mild variant of overt hypothyroidism. Patients with subclinical hypothyroidism should be informed about the disease and offered the possibility of replacement. Only some patients treated for subclinical hypothyroidism will feel better after therapy. In elderly patients on replacement therapy, care should include estimation of serum TSH level once or twice a year, with small dosage adjustments of levothyroxine sodium to keep serum TSH level within the normal range.
一定程度的甲状腺功能减退在老年人中很常见。它影响5%至20%的女性和3%至8%的男性。其发病率因遗传因素而异,在白种人中患病率较高,并且在碘摄入量高的人群中该疾病更常见。甲状腺功能减退的常见原因是甲状腺自身免疫性破坏以及既往甲状腺手术或放射性碘治疗。包括胺碘酮、细胞因子和锂在内的各种药物常常会诱发甲状腺功能减退。症状可能不典型,对于老年受试者未确诊的疾病,血清促甲状腺激素(TSH)水平的测定应作为生化检查的一部分。血清TSH水平升高的结果应通过重复检测来确认,并补充甲状腺素(T4)水平和甲状腺过氧化物酶抗体的测定,以验证、量化并对异常进行分类。推荐且合适的甲状腺功能减退替代疗法是左甲状腺素钠。如果怀疑有心脏病,初始替代剂量应较低。由于左甲状腺素钠的半衰期长,可通过每周增减1至2片进行小剂量调整。左甲状腺素钠口服后仅部分被吸收,食物、矿物质、药物和片剂成分会影响吸收。几年前进行的研究表明,左甲状腺素钠和碘塞罗宁联合使用可能会改善临床效果,但最近更全面的研究并未支持这一假设。因此,尚无证据表明碘塞罗宁替代有益。如果添加碘塞罗宁进行替代,碘塞罗宁的剂量应保持在较低水平,在生理范围内,最好每日服用两次。对于血清TSH水平和T4水平正常的老年人,甲状腺激素治疗并不比安慰剂更有益。左甲状腺素钠治疗的主要风险是替代过量,不良反应包括焦虑、肌肉消瘦、骨质疏松和心房颤动。血清TSH水平升高但T4水平在实验室参考范围内的亚临床甲状腺功能减退是显性甲状腺功能减退的一种轻度变体。应告知亚临床甲状腺功能减退患者该疾病,并提供替代治疗的可能性。只有部分接受亚临床甲状腺功能减退治疗的患者在治疗后会感觉好转。对于接受替代治疗的老年患者,护理应包括每年评估1至2次血清TSH水平,对左甲状腺素钠进行小剂量调整以使血清TSH水平保持在正常范围内。